Select patients with a normal contralateral kidney who have small ... While upper-tract transitional cell carcinoma (TCC) accounts for only 5% of urothelial malignancies, evidence suggests ...

Figure 1: Characterization of the hybrid cell vaccine. The hybrid cell vaccination was well tolerated by all patients. There were no serious adverse effects or any clinical signs of autoimmune ...

While upper-tract transitional cell carcinoma (TCC) accounts for only 5% of urothelial malignancies, evidence suggests that the frequency of these lesions is increasing Radical nephroureterectomy ...

Personalized cancer vaccines showed significant immune responses in stage III/IV renal cell carcinoma patients, with T-cells increasing 166-fold and persisting for up to three years. The vaccine ...

Overexpression of PLCG2 and TMEM38A inhibit tumor progression in clear cell renal cell carcinoma. February 7, 2025 New Mediastinal and Hilar Lymphadenopathy After Adjuvant Pembrolizumab in a Patient ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults.

Li et al. show that the TFE3 driver fusion transcriptionally upregulates an OXPHOS programme in translocation renal cell carcinoma that renders this cancer vulnerable to reductive stress ...

"We want to improve post-surgery treatment options that reduce the risk of the cancer coming back," he added in a Yale news release. The findings were published Feb. 5 in the journal Nature. The new ...

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell carcinoma (RCC) patients.

The new trial focused on patients with advanced, stage 3 or 4 clear cell renal [kidney] cell carcinoma. Immune-centered therapies against cancer cells already exist, but they aren't engineered to ...

The vaccines are designed to train the body’s immune system to recognise and destroy cancer cells to prevent relapse. According to the study titled, “A neoantigen vaccine generates antitumour immunity ...